摘要
目的探讨不同剂量替加环素联合氨基糖苷类治疗重症监护室(ICU)耐药鲍曼不动杆菌引起的重症肺炎患者的效果。方法选取我院2016年7月~2019年7月收治的90例ICU耐药鲍曼不动杆菌引起的重症肺炎患者作为研究对象,采用随机数字表法分为对照组与研究组,每组各45例。对照组予以常规剂量替加环素联合氨基糖苷类抗菌药治疗,研究组予以高剂量替加环素联合氨基糖苷类抗菌药治疗。比较两组患者的细菌清除率、急性生理及慢性健康状况评分(APACHEⅡ评分)、感染性炎性反应评分(SOFA评分)、不良反应总发生率及死亡率。结果研究组患者治疗后的细菌清除率高于对照组,差异有统计学意义(P<0.05);研究组患者治疗后的SOFA评分、APACHEⅡ评分、病死率低于对照组,差异有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论高剂量替加环素联合氨基糖苷类治疗ICU耐药鲍曼不动杆菌引起的重症肺炎患者的效果较好,可明显提高机体细菌清除率,并能够降低患者的死亡率,且具有较高的用药安全性,值得在临床推广。
Objective To investigate the effect of different doses of Tigecycline combined with aminoglycosides in the treatment of patients with severe pneumonia caused by ICU-resistant Acinetobacter baumannii.Methods A total of 90 patients with severe pneumonia caused by ICU-resistant Acinetobacter baumannii treated in our hospital from July 2016 to July 2019 were selected as the research object,according to random number table method,they were divided into the control group and the study group,45 cases in each group.The control group was treated with conventional doses of Tigecycline combined with aminoglycoside antibacterials,and the study group was treated with high doses of Tigecycline combined with aminoglycoside antibacterials.The bacterial clearance rate,SOFA score,APACHEⅡscore,the incidence rate of adverse reaction and mortality between the two groups were compared.Results The bacterial clearance rate of patients in the study group was higher than that in the control group,and the differences was statistically significant(P<0.05).The SOFA score,APACHEⅡscore and mortality rate of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion High dose Tigecycline combined with aminoglycosides in the treatment of patients with severe pneumonia caused by ICU-resistant Acinetobacter baumannii has good effect,which can significantly improve the body′s bacterial clearance rate,and reduce the mortality of patients,it has high drug safety,which is worthy of clinical promotion.
作者
苏航
刚丽
SU Hang;GANG Li(EICU,Zhongshan Hospital Affiliated to Dalian University,Liaoning Province,Dalian 116001,China)
出处
《中国当代医药》
2020年第23期47-49,共3页
China Modern Medicine
